MedTrace Logo

A PET Study to Determine Biodistribution and Binding Characteristics of [11C]AZ14132516 in Healthy Participants

NCT05818514 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-07-14

No results posted yet for this study

Summary

The purpose of this study is to measure the regional distribution and binding of \[11C\]AZ14132516 to CCR9 in the abdomen using PET-CT examination in healthy participants.

Study details include:

The study duration will be up to 60 days.

The IV radioligand \[11C\]AZ14132516 will be administered at PET-CT examination: Visit 2 for the pilot panel; Visit 2 and 3 in the main panel.

There will be 2 study visits for the pilot panel and 3 study visits for the main panel.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[11C]AZ14132516

Injection of radioligand for PET examinations

Sponsors & Collaborators

Principal Investigators

  • Per Stenkrona · Karolinska Institutet

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-27
Primary Completion
2023-07-11
Completion
2023-07-11

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05818514 on ClinicalTrials.gov